Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience.

Emiliano BarbieriMonica MaccaferriGiovanna LeonardiFrancesca GiacobbiGiorgia CorradiniIvana LagrecaPatrizia BarozziLeonardo PotenzaRoberto MarascaMario Luppi

Published in: Annals of hematology (2022)

Keyphrases

multiple myeloma
nucleic acid
cross sectional
copy number
adverse drug
emergency department
acute lymphoblastic leukemia
hodgkin lymphoma